摘要
目的:比较贝伐珠单抗治疗非鳞非小细胞肺癌(NSCLC)发生肿瘤空洞后的各种评价方法,为临床评估提供合理选择。方法:利用中国知网、万方数据、PubMed等数据库检索2008年1月~2022年9月期间发表的相关文献,总结归纳国内外肿瘤评估方法。结果:对使用抗血管生成类药物治疗后发生显著肿瘤空洞的患者进行肿瘤评估时,若采用实体瘤疗效评价标准1.1版(RECIST 1.1)评估,可能会对药物的临床疗效评价造成偏差。相较于经典的RECIST 1.1,采用改良版实体瘤疗效评价标准(mRECIST)、三维体积测量法、新响应标准(NRC)等方法评价肿瘤空洞亦具有各自的优势与特点。结论:三维体积测量法需考虑剔除空洞部分体积进行计算;NRC目前未在NSCLC治疗领域得到广泛验证;对于治疗后发生显著空洞的患者采用mRECIST可更灵敏地反映患者的肿瘤发展变化。
Objective:To compare available tumor evaluation methods for patients with non-squamous non-small cell lung cancer(NSCLC)who develop tumoral cavitation following bevacizumab treatment to determine the justified clinical tumor evaluation method.Methods:Clinical tumor evaluation methods retrieved in China domestic and abroad literatures published during January 2008 to September 2022 in databases including CNKI,Wanfang Data,PubMed were analyzed and summarized.Results:The clinical efficacy evaluation may be biased if the response evaluation criteria in solid tumors version 1.1(RECIST 1.1)was used in the tumor evaluation of patients who develop significant tumoral cavitation following treatment with antiangiogenic agents.Compared with the classic RECIST 1.1,modified RECIST(mRECIST),threedimensional volume measurement,and new response criteria(NRC)demonstrated advantages and unique characteristics in the evaluation of tumoral cavitation.Conclusion:The cavitation volume is excluded in the three-dimensional volume measurement.The NRC has not been extensively validated in the treatment of NSCLC.The tumor progression can be sensitively captured with mRECIST for patients who develop significant tumoral cavitation following treatment.
作者
黄玉宝
苏晶
彭晶玉
李松松
邹红霞
胡利
庄巍
杨云凯
HUANG Yu-bao;SU Jing;PENG Jing-yu;LI Song-song;ZOU Hong-xia;HU Li;ZHUANG Wei;YANG Yun-kai(China National Biotec Group Company Limited,Clinical Medicine Center,Beijing 100024,China)
出处
《中国合理用药探索》
2023年第4期68-74,共7页
Chinese Journal of Rational Drug Use
关键词
贝伐珠单抗
空洞
评价标准
实体瘤疗效评价标准
非鳞非小细胞肺癌
bevacizumab
cavitation
evaluation criterion
response evaluation criteria in solid tumors
nonsquamous non-small cell lung cancer
